« Return to News | Awards & Advancement

Icon appoints Professor Brendan Buckley chief medical officer

Tuesday, July 9, 2013 10:33 AM

Global CRO Icon has appointed professor Brendan Buckley chief medical officer. Professor Buckley will be Icon’s lead medical expert, representing the company’s position on scientific, ethical and medical governance matters and provide guidance and oversight to the medical and scientific groups across Icon.

An endocrinologist with over 30 years’ experience, Brendan joined Icon through the acquisition of Firecrest Clinical in 2011, where he was one of the company’s founders and senior vice president of Medical Affairs. 

Brendan has extensive experience in trials and chairs several independent Data and Safety Monitoring Boards for medium to large cardio-metabolic and rare disease clinical studies. Brendan is clinical professor of Medicine and Pharmacology at the School of Medicine, University College Cork (UCC), Ireland, and also has been director of the university’s European Center for Clinical Trials in Rare Diseases.

He has been a board member of the Irish Medicines Board and the EMA’s Scientific Advisory Group for Diabetes and Endocrinology since 2005. He also was a member of the EMA Committee for Orphan Medicinal Products from 2000 to 2003 and a member of the EMA’s panel of experts. Professor Buckley also is chairman of the Irish Statutory Anti-Doping Agency and is a member of the U.K. Anti-Doping Scientific Advisory Board. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.